Antimicrobials
Imipenem/Cilastatin/Relebactam

Imipenem/Cilastatin/Relebactam

Restricted

Medium
N/A
1.25 g: $267.50 7-14 days of therapy: $7,490-14,980

Spectrum of Activity

Dosing

General Information

FDA approved for

  • Hospital-acquired and ventilator-associated bacterial pneumonia in adults with limited or no treatment options
  • Complicated urinary tract infections in adults who have limited or no alternative treatment options
  • Complicated intra-abdominal infections in adults who have limited or no alternative treatment options

Tier 4 Protected Antimicrobial

  • May be ordered by an ID physician for the defined use-criteria, if specified. If a non-ID prescriber orders a restricted antimicrobial, Pharmacy will contact the prescriber to notify him or her of this status and to select an alternative antimicrobial. If the restricted antimicrobial is necessary or is a continuation of a home medication, the prescriber must place a consult for an ID specialist to assess the necessity of this antimicrobial. Once the consult has been placed, Pharmacy will dispense the medication. These agents will be monitored by the ASP/Pharmacy and utilization/compliance reported quarterly.

Non-Formulary Antimicrobial

  • Requires approval from Antimicrobial Stewardship Subcommittee Chairpersons, regardless of inpatient or outpatient status. These medications are not stocked in the Pharmacy and require 24-48 hours for approval and procurement of the drug.

Periodic renal function tests; signs of hypersensitivity/anaphylaxis

  • Headache
  • Diarrhea
  • Nausea
  • Elevated LFTs

Ganciclovir:

  • Risk of seizures

Valproic Acid:

  • Increases risk of breakthrough seizures

Imipenem:

  • Disrupts bacterial cell wall synthesis by inhibiting PBPs

Cilastatin:

  • DHP inhibitor

Relebactam:

  • Inactivates beta-lactamase diazabicyclooctane core

Recarbrio